Tevimbra Prices, Coupons, Copay Cards & Patient Assistance
Tevimbra (tislelizumab) is a member of the anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) drug class and is commonly used for Esophageal Carcinoma, and Gastric Cancer.
The cost for Tevimbra (jsgr 10 mg/mL) intravenous solution is around $5,843 for a supply of 10 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Tevimbra prices
Intravenous Solution
jsgr 10 mg/mL
Tevimbra intravenous solution
from $5,842.93
for 10 milliliters
Quantity | Per unit | Price |
---|---|---|
10 milliliters | $584.29 | $5,842.93 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Tevimbra Coupons, Copay Cards and Rebates
Tevimbra offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
No manufacturer promotions could be found for this medication.
Patient Assistance & Copay Programs for Tevimbra
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: myBeOne Support Program
Eligibility requirements:- Determined case by case
- Based on FPL
- FDA-approved diagnosis
- Must be residing in the US or a US territory, and under the care of a US physician
- Co-payment assistance, reimbursement support, and patient assistance programs are available for eligible patients. This program may provide a Bridge Program for eligible patients. Contact program for details.
- Tevimbra (tislelizumab) Injection
More information please phone: 833-234-4363 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Taxotere
Taxotere (docetaxel) treats breast cancer, lung cancer, prostate cancer and stomach cancer. Learn ...
Lonsurf
Lonsurf is an oral combination tablet that contains tipiracil and trifluridine which may be used to ...
Trazimera
Trazimera (trastuzumab-qyyp) is a biosimilar to Herceptin that may be used to treat certain types ...
More about Tevimbra (tislelizumab)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español